Clinical trials: Botulinum toxin type A, completed
Overactive Bladder
Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?
The purpose of this research study is to help determine if 10 injections of Botox ® 100 units is less painful than 20 injections of Botox ® 100 units based on effectiveness in reducing urge incontinence episodes.
- Trial name
- NCT04124939
- Testing
- OnabotulinumtoxinA 100 Units
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Wake Forest University Health Sciences
Glabellar Frown Lines
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03736928
- Testing
- AbobotulinumtoxinA dose level 1 or 2, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4
- Where
- 10 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA II (NCT04622254)
- Testing
- NT 201
- Where
- 12 sites in Germany
- Volunteers
- 368 people
- Sponsor
- Merz North America, Inc.
Moderate to Severe Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
The study objective is to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on…
- Trial name
- NCT00770211
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- 8 sites in United States
- Volunteers
- 271 people
- Sponsor
- Merz Pharmaceuticals GmbH
Platysma Prominence
BOTOX® for the Treatment of Platysma Prominence
To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.
- Trial name
- NCT03915067
- Testing
- BOTOX® purified neurotoxin complex
- Where
- 12 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- Allergan
Urinary Incontinence, Urge
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
The purpose of this randomized, open-label, active-control trial is to compare the effectiveness of intra-detrusor botulinum toxin A (Botox A®, Allergan) versus sacral neuromodulation (InterStim®, Medtronic) for the treatment of…
- Trial name
- ROSETTA (NCT01502956)
- Testing
- InterStim® device, Botox® injection
- Where
- 9 sites in United States
- Volunteers
- 386 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Adductor Spasmodic Dysphonia, Voice Disorders
DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Spasmodic Dysphonia (SD) is a neurologic condition causing inappropriate contraction of the laryngeal musculature, leading to abnormal voicing.
- Conditions
- Adductor Spasmodic Dysphonia, Voice Disorders, Spasmodic Dysphonia
- Trial name
- NCT05158166
- Testing
- DaxibotulinumtoxinA
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Francisco
Hyperhidrosis
Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT02479139
- Testing
- Vehicle, ANT-1207
- Where
- 19 sites in United States
- Volunteers
- 145 people
- Sponsor
- Allergan
Frown Lines
Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
The purpose of the study is to provide preliminary comparative data on BoNT/A-DP versus Botox Cosmetic. Subsequently the sample size is primarily based on clinical judgement and practical considerations.
- Trial name
- H2H (NCT04763265)
- Testing
- Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 208 people
- Sponsor
- Croma-Pharma GmbH
Moderate to Severe Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2
The study objective was to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on…
- Trial name
- NCT00770029
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- 8 sites in United States, Canada
- Volunteers
- 276 people
- Sponsor
- Merz Pharmaceuticals GmbH
Cervical Dystonia, Blepharospasm
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical…
- Trial name
- NCT01814774
- Testing
- No Intervention
- Where
- 2 sites in Norway, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Allergan
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01224015
- Testing
- normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 684 people
- Sponsor
- Allergan
Glabellar Lines
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines.
- Trial name
- NCT00512135
- Testing
- IncobotulinumtoxinA (Xeomin) (20 units)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 801 people
- Sponsor
- Merz Pharmaceuticals GmbH
Pediatrics, Muscle Spasticity
BOTOX® Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603602
- Testing
- botulinum toxin Type A
- Where
- 45 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Allergan
Urinary Incontinence
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
This study will evaluate the 3 doses of onabotulinumtoxinA (botulinum toxin Type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to…
- Trial name
- NCT01852045
- Testing
- OnabotulinumtoxinA
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 114 people
- Sponsor
- Allergan
Glabellar Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
- Trial name
- NCT03014635
- Testing
- Botulinum Toxins, Type A
- Where
- 14 sites in United States, Canada
- Volunteers
- 306 people
- Sponsor
- Revance Therapeutics, Inc.
Cervical Dystonia, Spasmodic Torticollis
Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis
To evaluate efficacy and safety of E2014 (2500U, 5000U, 10000U, placebo) in a multicenter, randomized, double-blind, parallel group comparative study by intramuscularly administering to patients with spasmodic torticollis.
- Trial name
- NCT00165776
- Testing
- BOTULINUM TOXIN TYPE B
- Where
- 21 sites in Japan
- Volunteers
- 133 people
- Sponsor
- Eisai Co., Ltd.
Chronic Migraine
A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
The purpose of this study is to evaluate sustained tolerability, quality of life, and change in cognitive efficiency following treatment with OnabotulinumtoxinA and daily topiramate vs.
- Trial name
- NCT01700387
- Testing
- onabotulinumtoxinA, Topiramate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cady, Roger, M.D.
Cosmetic Techniques
Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation.
- Trial name
- JBDX (NCT05167864)
- Testing
- Onabotulinumtoxina for Injection, Abobotulinumtoxina for Injection, IncobotulinumtoxinA for Injection
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- University of Pennsylvania
Cervical Dystonia
Dystonia Treatment With Injections Supplemented By Transcranial Magnetic Stimulation
We applied 16 sessions of rTMS over 4 consecutive days for adult patients suffering from cervical dystonia who received botulinum toxin (BoNT) injections on a regular basis.
- Trial name
- D-TWIST (NCT04916444)
- Testing
- rTMS
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Florida